Nature Communications (Nov 2020)
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer
- Mélanie Desbois,
- Akshata R. Udyavar,
- Lisa Ryner,
- Cleopatra Kozlowski,
- Yinghui Guan,
- Milena Dürrbaum,
- Shan Lu,
- Jean-Philippe Fortin,
- Hartmut Koeppen,
- James Ziai,
- Ching-Wei Chang,
- Shilpa Keerthivasan,
- Marie Plante,
- Richard Bourgon,
- Carlos Bais,
- Priti Hegde,
- Anneleen Daemen,
- Shannon Turley,
- Yulei Wang
Affiliations
- Mélanie Desbois
- Department of Oncology Biomarker Development, Genentech, Inc.
- Akshata R. Udyavar
- Department of Bioinformatics & Computational Biology, Genentech, Inc.
- Lisa Ryner
- Department of Oncology Biomarker Development, Genentech, Inc.
- Cleopatra Kozlowski
- Department of Oncology Biomarker Development, Genentech, Inc.
- Yinghui Guan
- Department of Oncology Biomarker Development, Genentech, Inc.
- Milena Dürrbaum
- Department of Bioinformatics & Computational Biology, Genentech, Inc.
- Shan Lu
- Department of Oncology Biomarker Development, Genentech, Inc.
- Jean-Philippe Fortin
- Department of Bioinformatics & Computational Biology, Genentech, Inc.
- Hartmut Koeppen
- Department of Research Pathology, Genentech, Inc.
- James Ziai
- Department of Research Pathology, Genentech, Inc.
- Ching-Wei Chang
- Department of Biostatistics, Genentech, Inc.
- Shilpa Keerthivasan
- Department of Cancer Immunology, Genentech, Inc.
- Marie Plante
- Laval University Cancer Research Center, Hôtel-Dieu-de-Québec, Centre Hospitalier Universitaire (CHU) de Québec
- Richard Bourgon
- Department of Bioinformatics & Computational Biology, Genentech, Inc.
- Carlos Bais
- Department of Oncology Biomarker Development, Genentech, Inc.
- Priti Hegde
- Department of Oncology Biomarker Development, Genentech, Inc.
- Anneleen Daemen
- Department of Bioinformatics & Computational Biology, Genentech, Inc.
- Shannon Turley
- Department of Cancer Immunology, Genentech, Inc.
- Yulei Wang
- Department of Oncology Biomarker Development, Genentech, Inc.
- DOI
- https://doi.org/10.1038/s41467-020-19408-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
The exclusion of T cells from solid tumours is a potentially important mechanism that regulates whether or not cancer patients respond well to checkpoint blocking immunotherapies. Here the authors identify immune phenotypes and mediators of T cell exclusion among ovarian cancer patient samples from the ICON7 phase III trial.
